Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Keefe

Showing results (181-190 of 188) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 188 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 27, 2016
Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trialS M Keefe, J Hoffman-Censits, R B Cohen, et al.
JAMA Oncology|December 14, 2023
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical TrialKrishnansu S Tewari, Nicoletta Colombo, Bradley J Monk, et al.
Journal of Molecular and Cellular Cardiology|February 26, 2023
Caveolin-3 and Caveolae regulate ventricular repolarizationYogananda S Markandeya, Zachery R Gregorich, Li Feng, et al.
Gynecologic Oncology|October 20, 2023
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100Jonathan A Ledermann, Ronnie Shapira-Frommer, Alessandro D Santin, et al.
Physical Review Letters|May 30, 2015
Evidence of soft dipole resonance in ^{11}li with isoscalar characterR Kanungo, A Sanetullaev, J Tanaka, et al.
Lancet (London, England)|September 17, 2024
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trialDomenica Lorusso, Yang Xiang, Kosei Hasegawa, et al.
Lancet (London, England)|March 23, 2024
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trialDomenica Lorusso, Yang Xiang, Kosei Hasegawa, et al.
Human Molecular Genetics|May 23, 2003
Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiencyN A Alam, A J Rowan, N C Wortham, et al.
Pageof 19

Showing results (181-190 of 188) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 188 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 27, 2016
Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trialS M Keefe, J Hoffman-Censits, R B Cohen, et al.
JAMA Oncology|December 14, 2023
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical TrialKrishnansu S Tewari, Nicoletta Colombo, Bradley J Monk, et al.
Journal of Molecular and Cellular Cardiology|February 26, 2023
Caveolin-3 and Caveolae regulate ventricular repolarizationYogananda S Markandeya, Zachery R Gregorich, Li Feng, et al.
Gynecologic Oncology|October 20, 2023
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100Jonathan A Ledermann, Ronnie Shapira-Frommer, Alessandro D Santin, et al.
Physical Review Letters|May 30, 2015
Evidence of soft dipole resonance in ^{11}li with isoscalar characterR Kanungo, A Sanetullaev, J Tanaka, et al.
Lancet (London, England)|September 17, 2024
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trialDomenica Lorusso, Yang Xiang, Kosei Hasegawa, et al.
Lancet (London, England)|March 23, 2024
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trialDomenica Lorusso, Yang Xiang, Kosei Hasegawa, et al.
Human Molecular Genetics|May 23, 2003
Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiencyN A Alam, A J Rowan, N C Wortham, et al.
Pageof 19